APA

Xia G., Chen W., Zhang J., Shao J., Zhang Y., Huang W., Zhang L., Qi W., Sun X., Li B., Xiang Z., Ma C., Xu J., Deng H., Li Y., Li P., Miao H., Han J., Liu Y., Shen J. & Yu Y. (20150226). A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. : Journal of medicinal chemistry.

Chicago

Xia Guangxin, Chen Wenteng, Zhang Jing, Shao Jiaan, Zhang Yong, Huang Wei, Zhang Leduo, Qi Weixing, Sun Xing, Li Bojun, Xiang Zhixiong, Ma Chen, Xu Jia, Deng Hailin, Li Yufeng, Li Ping, Miao Hong, Han Jiansheng, Liu Yanjun, Shen Jingkang and Yu Yongping. 20150226. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. : Journal of medicinal chemistry.

Harvard

Xia G., Chen W., Zhang J., Shao J., Zhang Y., Huang W., Zhang L., Qi W., Sun X., Li B., Xiang Z., Ma C., Xu J., Deng H., Li Y., Li P., Miao H., Han J., Liu Y., Shen J. and Yu Y. (20150226). A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. : Journal of medicinal chemistry.

MLA

Xia Guangxin, Chen Wenteng, Zhang Jing, Shao Jiaan, Zhang Yong, Huang Wei, Zhang Leduo, Qi Weixing, Sun Xing, Li Bojun, Xiang Zhixiong, Ma Chen, Xu Jia, Deng Hailin, Li Yufeng, Li Ping, Miao Hong, Han Jiansheng, Liu Yanjun, Shen Jingkang and Yu Yongping. A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles. : Journal of medicinal chemistry. 20150226.